CA3010915C - Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions - Google Patents
Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Download PDFInfo
- Publication number
- CA3010915C CA3010915C CA3010915A CA3010915A CA3010915C CA 3010915 C CA3010915 C CA 3010915C CA 3010915 A CA3010915 A CA 3010915A CA 3010915 A CA3010915 A CA 3010915A CA 3010915 C CA3010915 C CA 3010915C
- Authority
- CA
- Canada
- Prior art keywords
- active agent
- manganese
- pharmaceutically acceptable
- acceptable salt
- dpdp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277232P | 2016-01-11 | 2016-01-11 | |
| US62/277,232 | 2016-01-11 | ||
| US201662361605P | 2016-07-13 | 2016-07-13 | |
| US62/361,605 | 2016-07-13 | ||
| PCT/IB2017/050115 WO2017122120A1 (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3010915A1 CA3010915A1 (en) | 2017-07-20 |
| CA3010915C true CA3010915C (en) | 2024-06-04 |
Family
ID=57909814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3010915A Active CA3010915C (en) | 2016-01-11 | 2017-01-10 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11260060B2 (enExample) |
| EP (2) | EP3402475B1 (enExample) |
| JP (2) | JP7311267B2 (enExample) |
| CN (1) | CN108601757A (enExample) |
| AU (1) | AU2017208123B2 (enExample) |
| CA (1) | CA3010915C (enExample) |
| RU (1) | RU2018128793A (enExample) |
| WO (1) | WO2017122120A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3402475B1 (en) * | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| RU2693677C1 (ru) * | 2018-10-15 | 2019-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ гемокоррекции при лечении печеночной недостаточности |
| JP2022533672A (ja) * | 2019-05-21 | 2022-07-25 | ペンデュラム セラピューティクス， インコーポレイテッド | 肝障害を処置するための方法および組成物 |
| WO2022269026A1 (en) | 2021-06-25 | 2022-12-29 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Treating acetaminophen overdose |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566401B2 (en) * | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| US20050070607A1 (en) | 2003-08-19 | 2005-03-31 | James Andrus | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions |
| EP1877044A4 (en) * | 2005-04-21 | 2009-09-02 | Glenn A Goldstein | AMIDE N-ACETYLCYSTEINE (AMIDE NAC) FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH OXIDATIVE STRESS |
| CA2667052A1 (en) | 2006-10-23 | 2008-05-02 | The Mental Health Research Institute Of Victoria | Combination therapy |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| WO2011004325A1 (en) | 2009-07-06 | 2011-01-13 | Pledpharma Ab | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound |
| AU2012364227B2 (en) | 2012-01-05 | 2017-12-07 | Egetis Therapeutics Ab | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
| US20140178358A1 (en) * | 2012-12-21 | 2014-06-26 | The United States of America as represented by the Secretary of Department of Health and Human Servi | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker |
| EP3402475B1 (en) | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
-
2017
- 2017-01-10 EP EP17701925.4A patent/EP3402475B1/en not_active Not-in-force
- 2017-01-10 CN CN201780006292.1A patent/CN108601757A/zh active Pending
- 2017-01-10 EP EP21158979.1A patent/EP3842040B1/en active Active
- 2017-01-10 US US16/068,626 patent/US11260060B2/en active Active
- 2017-01-10 WO PCT/IB2017/050115 patent/WO2017122120A1/en not_active Ceased
- 2017-01-10 RU RU2018128793A patent/RU2018128793A/ru unknown
- 2017-01-10 CA CA3010915A patent/CA3010915C/en active Active
- 2017-01-10 JP JP2018555315A patent/JP7311267B2/ja active Active
- 2017-01-10 AU AU2017208123A patent/AU2017208123B2/en active Active
-
2021
- 2021-12-03 JP JP2021197319A patent/JP7374163B2/ja active Active
-
2022
- 2022-01-14 US US17/576,197 patent/US12303516B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018128793A (ru) | 2020-02-13 |
| EP3842040A1 (en) | 2021-06-30 |
| EP3402475B1 (en) | 2021-10-20 |
| US20220133739A1 (en) | 2022-05-05 |
| US12303516B2 (en) | 2025-05-20 |
| WO2017122120A1 (en) | 2017-07-20 |
| JP7311267B2 (ja) | 2023-07-19 |
| EP3402475A1 (en) | 2018-11-21 |
| CN108601757A (zh) | 2018-09-28 |
| AU2017208123A1 (en) | 2018-07-19 |
| EP3842040B1 (en) | 2022-03-09 |
| RU2018128793A3 (enExample) | 2020-05-25 |
| JP2022019973A (ja) | 2022-01-27 |
| US20190015424A1 (en) | 2019-01-17 |
| US11260060B2 (en) | 2022-03-01 |
| JP7374163B2 (ja) | 2023-11-06 |
| JP2019501226A (ja) | 2019-01-17 |
| AU2017208123B2 (en) | 2022-04-21 |
| CA3010915A1 (en) | 2017-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12303516B2 (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| Fishbane | N-acetylcysteine in the prevention of contrast-induced nephropathy | |
| McGregor et al. | Rationale and impact of vitamin C in clinical nutrition | |
| Gawarammana et al. | Medical management of paraquat ingestion | |
| Pinheiro et al. | Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension | |
| JP6591995B2 (ja) | ドーパデカルボキシラーゼ阻害剤組成物 | |
| WO2005017094A2 (en) | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency | |
| EP1379232B1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| Skinner | Nephrotoxicity—what do we know and what don't we know? | |
| CA2647297A1 (en) | Anti-cancer activity augmentation compounds and formulations and methods of use thereof | |
| CN103038356A (zh) | 乙酰半胱氨酸组合物及其使用方法 | |
| AKARSU et al. | Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report | |
| ES2593038T3 (es) | Nuevo tratamiento para la amiloidosis asociada a transtirretina | |
| Mandal et al. | In vivo assessment of bacteriotherapy on acetaminophen-induced uremic rats | |
| JP2019501226A5 (enExample) | ||
| Yang et al. | 4-Phenylbutyrate benefits traumatic hemorrhagic shock in rats by attenuating oxidative stress, not by attenuating endoplasmic reticulum stress | |
| WO2003063780A2 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
| Gurung et al. | mRNA therapy restores ureagenesis and corrects glutathione metabolism in argininosuccinic aciduria | |
| Iwasa et al. | Usefulness of levocarnitine and/or branched-chain amino acids during invasive treatment for hepatocellular carcinoma | |
| Smith | Drugs and pharmaceuticals: management of intoxication and antidotes | |
| Rahimi et al. | Novel ammonia-lowering agents for hepatic encephalopathy | |
| Kociancic et al. | Acetaminophen intoxication and length of treatment: how long is long enough? | |
| HK40056482B (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| HK40056482A (en) | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | |
| Patel et al. | Amlodipine overdose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211215 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241129 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241129 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241129 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260105 |